P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL
Introduction: Hepatitis B and C infection are responsible for more than 300 million of chronic liver disease patients all over the world. One goal of WHO 2030 agenda is the eradication of hepatitis B and C. However poverty is a great obstacle to achieve this goal. In Brazil, more than 13 million of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-09-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268121001769 |
| _version_ | 1818865624268406784 |
|---|---|
| author | Livia Melo Villar Aline Borges Cardoso Juliana Custódio Miguel Elisangela Ferreira da Silva Julia Trece Marques Giselle Prado do Nascimento Barbara Vieira do Lago |
| author_facet | Livia Melo Villar Aline Borges Cardoso Juliana Custódio Miguel Elisangela Ferreira da Silva Julia Trece Marques Giselle Prado do Nascimento Barbara Vieira do Lago |
| author_sort | Livia Melo Villar |
| collection | DOAJ |
| description | Introduction: Hepatitis B and C infection are responsible for more than 300 million of chronic liver disease patients all over the world. One goal of WHO 2030 agenda is the eradication of hepatitis B and C. However poverty is a great obstacle to achieve this goal. In Brazil, more than 13 million of people live in poverty (PLP) and could be vulnerable to HBV and HCV. Objectives: This study aims to determine HBV and HCV prevalence and analyze the response to HBV vaccination by measuring anti -HBs antibodies in serum samples from PLP. Methods: This was a cross sectional study carried out in rural settlement in the municipality of Sao Joao do Piaui, Northeast Brazil in March and July 2019. Participants were recruited in their homes and after signing the informed consent, they gave blood samples. A commercial ELISA was use d for measurements of antibodies against i) hepatitis B surface antigen (anti-HBs) and ii) hepatitis B core antigen (HBc) and of the hepatitis surf ace antigen (HBsAg). Nearly half of the population was female (51.0%). The mean age was 36.2±20.4 years, and about 43.2% received a monthly income of approximately $35.00 USD. Most are selfdeclared black or mixed race (81.9%), were married (50.1%), 15.5% was illiterate and 25.8% had a maximum of six years of formal schooling. Overall zero positivity for HBsAg, anti-HBc and anti -HBs determined by ELISA was 0.2%, 5.1 % and 43.9%, respectively. Anti-HBs reactivity was not associated with monthly income and schooling. Low rates of vaccination against hepatitis B were found among PLP in Northeast Brazil, highlighting the need for preventive actions towards this population segment, vulnerable and a potential disseminator of this infection. Strategies to increase HBV vaccination will be essential to eradicate hepatitis Band achieve the goals of WHO 2030 agenda. Report the levels of biochemical markers in CLD patients with or without COVID-19 to give more information that could help clinical monitoring.Study was approved by Brazilian Ethics Committee. Blood samples were collected after signed informed consent. Results: Most of individuals were male 56% (37/66) and mean age of population was 49±17 years. Six out 66 CLD patients were SARS CoV-2 RNA positive at baseline. At the end of follow-up, all of these 6 patients achieved SARS-CoV-2 clearance. At least once during follow-up, the CLD group versus CLD/COVID-19 group, 48% (29/60) vs. 17% (1/6) (P = 0.2) had abnormal alanine aminotransferase; 47% (28/60) vs. 17% (1/6) had abnormal aspartate aminotransferase (P = 0.21); 60% (36/60) vs. 67% (4/6) had abnormal γ-glutamyl transferase (P = 1.00), 32% CLD patients (19/60) had abnormal total bilirubin levels vs. none of the CLD/COVID-19 group (P = 0.17). Conclusions: Previous liver disease did not seem to increase the biochemical levels, except GGT, during COVID-19 infection. However, liver function monitoring is still essential for both COVID-19 patients with and without liver disease. |
| first_indexed | 2024-12-19T10:50:30Z |
| format | Article |
| id | doaj.art-3d5cc1d8f62f43d8afa4ac904db052bc |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-19T10:50:30Z |
| publishDate | 2021-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-3d5cc1d8f62f43d8afa4ac904db052bc2022-12-21T20:25:01ZengElsevierAnnals of Hepatology1665-26812021-09-0124100477P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZILLivia Melo Villar0Aline Borges Cardoso1Juliana Custódio Miguel2Elisangela Ferreira da Silva3Julia Trece Marques4Giselle Prado do Nascimento5Barbara Vieira do Lago6Viral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilViral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilViral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilViral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilViral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilViral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilViral Hepatitis Laboratory, Oswaldo Cruz Foundation, Rio de Janeiro, BrazilIntroduction: Hepatitis B and C infection are responsible for more than 300 million of chronic liver disease patients all over the world. One goal of WHO 2030 agenda is the eradication of hepatitis B and C. However poverty is a great obstacle to achieve this goal. In Brazil, more than 13 million of people live in poverty (PLP) and could be vulnerable to HBV and HCV. Objectives: This study aims to determine HBV and HCV prevalence and analyze the response to HBV vaccination by measuring anti -HBs antibodies in serum samples from PLP. Methods: This was a cross sectional study carried out in rural settlement in the municipality of Sao Joao do Piaui, Northeast Brazil in March and July 2019. Participants were recruited in their homes and after signing the informed consent, they gave blood samples. A commercial ELISA was use d for measurements of antibodies against i) hepatitis B surface antigen (anti-HBs) and ii) hepatitis B core antigen (HBc) and of the hepatitis surf ace antigen (HBsAg). Nearly half of the population was female (51.0%). The mean age was 36.2±20.4 years, and about 43.2% received a monthly income of approximately $35.00 USD. Most are selfdeclared black or mixed race (81.9%), were married (50.1%), 15.5% was illiterate and 25.8% had a maximum of six years of formal schooling. Overall zero positivity for HBsAg, anti-HBc and anti -HBs determined by ELISA was 0.2%, 5.1 % and 43.9%, respectively. Anti-HBs reactivity was not associated with monthly income and schooling. Low rates of vaccination against hepatitis B were found among PLP in Northeast Brazil, highlighting the need for preventive actions towards this population segment, vulnerable and a potential disseminator of this infection. Strategies to increase HBV vaccination will be essential to eradicate hepatitis Band achieve the goals of WHO 2030 agenda. Report the levels of biochemical markers in CLD patients with or without COVID-19 to give more information that could help clinical monitoring.Study was approved by Brazilian Ethics Committee. Blood samples were collected after signed informed consent. Results: Most of individuals were male 56% (37/66) and mean age of population was 49±17 years. Six out 66 CLD patients were SARS CoV-2 RNA positive at baseline. At the end of follow-up, all of these 6 patients achieved SARS-CoV-2 clearance. At least once during follow-up, the CLD group versus CLD/COVID-19 group, 48% (29/60) vs. 17% (1/6) (P = 0.2) had abnormal alanine aminotransferase; 47% (28/60) vs. 17% (1/6) had abnormal aspartate aminotransferase (P = 0.21); 60% (36/60) vs. 67% (4/6) had abnormal γ-glutamyl transferase (P = 1.00), 32% CLD patients (19/60) had abnormal total bilirubin levels vs. none of the CLD/COVID-19 group (P = 0.17). Conclusions: Previous liver disease did not seem to increase the biochemical levels, except GGT, during COVID-19 infection. However, liver function monitoring is still essential for both COVID-19 patients with and without liver disease.http://www.sciencedirect.com/science/article/pii/S1665268121001769 |
| spellingShingle | Livia Melo Villar Aline Borges Cardoso Juliana Custódio Miguel Elisangela Ferreira da Silva Julia Trece Marques Giselle Prado do Nascimento Barbara Vieira do Lago P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL Annals of Hepatology |
| title | P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL |
| title_full | P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL |
| title_fullStr | P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL |
| title_full_unstemmed | P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL |
| title_short | P-117 LOW PREVALENCE OF HEPATITIS B AND C AMONG PEOPLE LIVING IN POVERTY IN NORTHEAST BRAZIL |
| title_sort | p 117 low prevalence of hepatitis b and c among people living in poverty in northeast brazil |
| url | http://www.sciencedirect.com/science/article/pii/S1665268121001769 |
| work_keys_str_mv | AT liviamelovillar p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil AT alineborgescardoso p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil AT julianacustodiomiguel p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil AT elisangelaferreiradasilva p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil AT juliatrecemarques p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil AT gisellepradodonascimento p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil AT barbaravieiradolago p117lowprevalenceofhepatitisbandcamongpeoplelivinginpovertyinnortheastbrazil |